Curanex Pharmaceuticals Inc. CURX 深 沪
已收盘 08-21 16:00:00 美东时间
4.71
-0.560
-10.63%
华盛通- 最 高5.38
- 今 开5.10
- 成交量 2.86万股
- 最 低 4.70
- 昨 收 5.27
- 总市值 1.48亿
- 52周最高 183.592
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 3.576
- 委 比 -86.81%
- 总股本 3136.48万
- 历史最高 183.592
- 量 比 0.05
- 振 幅 12.90%
- 历史最低 3.576
- 每 手 1
- 风险率 32.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Curanex Advances Phyto-N Program and Expands Indications
An announcement from Curanex Pharmaceuticals Inc. ( ($CURX) ) is now available....
05-14 21:54
Curanex Pharmaceuticals Q1 EPS $(0.11) Down From $(0.01) YoY
Curanex Pharmaceuticals (NASDAQ:CURX) reported quarterly losses of $(0.11) per share. This is a 1000 percent decrease over losses of $(0.01) per share from the same period last year.
05-14 21:05
Curanex Continues To Advance Phyto-N As Lead Development Candidate, With Ulcerative Colitis As Initial Target Indication; Co. Prepares Phyto-N For Planned IND Submission In Q4 Of 2026
Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitisExpanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition
05-14 20:56
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Immutep (NASDAQ:IMMP) shares rose 135.4% to $0.74 during Wednesday's p...
04-15 20:05
EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives
Curanex highlights patient cases suggesting its lead candidate may aid cachexia and severe disease recovery.
04-08 19:33
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases
Curanex expands pipeline with cancer cachexia, advances Phyto-N toward IND, and reports preclinical safety data.
04-02 19:53
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
Curanex Pharmaceuticals在制造、毒理学、专利和监管方面取得进展，推动其主要资产Phyto-N溃疡性结肠炎治疗IND申请。公司完成了GLP毒理学研究，扩大知识产权，并评估其他治疗领域。计划于2026年第四季度提交IND，并在澳大利亚启动I期临床，预计溃疡性结肠炎市场到2030年达113.9亿美元。
03-30 21:35
